Additionally, studies incorporating heterogenous tumors with combination strategies will be necessary to credential AXL as an effective therapy for the elimination of MES-specific neuroblastoma tumor cells and/or the treatment-resistant neuroblastomas. The gene discussed is AXL; the disease is neuroblastoma.